Calidi Biotherapeutics, Inc.
CLDWW- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCLDI
13F holders, Q4 2024
Institutional positions in Calidi Biotherapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1
- −15 vs. Q3 2024
- Shares held
- 105.0K
- −5.78M (−98.2%) vs. Q3 2024
- Total value
- $1.01K
- −$98.4K (−99.0%) vs. Q3 2024
- New holders
- 0
- 0 more added
- Sold out
- 15
- 0 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLDWW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $1.01K |
| Q3 2024 | 16 | $99.4K |
| Q2 2024 | 17 | $281.5K |
| Q1 2024 | 17 | $385.1K |
| Q4 2023 | 18 | $384.0K |
| Q3 2023 | 22 | $1.64M |
| Q2 2023 | 22 | $866.3K |
| Q1 2023 | 24 | $366.1K |
| Q4 2022 | 25 | $350.0K |
| Q3 2022 | 27 | $479.9K |
| Q2 2022 | 28 | $767.0K |
| Q1 2022 | 29 | $2.83M |
| Q4 2021 | 23 | $3.01M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Calidi Biotherapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Exos Asset Management LLC | 105,000 | $1.01K | 0.23% | 00.0% | Unchanged |
| Polar Asset Management Partners Inc. | 0 | $0 | 0.00% | −2,165,086−100.0% | Sold out |
| Highbridge Capital Management LLC | 0 | $0 | 0.00% | – | Sold out |
| Driehaus Capital Management LLC | 0 | $0 | 0.00% | −750,000−100.0% | Sold out |
| Finepoint Capital LP | 0 | $0 | 0.00% | −655,200−100.0% | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −599,702−100.0% | Sold out |
| Aristeia Capital LLC | 0 | $0 | 0.00% | −494,400−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −467,818−100.0% | Sold out |
| Shaolin Capital Management LLC | 0 | $0 | 0.00% | −330,547−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −171,536−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −70,701−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −36,469−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −20,052−100.0% | Sold out |
| Clear Street LLC | 0 | $0 | 0.00% | −6,617−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,398−100.0% | Sold out |
| Flow Traders U.S. LLC | 0 | $0 | 0.00% | −11,427−100.0% | Sold out |